In the past two years, global leaders in the biopharmaceutical industry have increasingly invested in the Chinese market, making the healthcare and pharmaceutical sector a popular destination for foreign investment.

In 2024, the Danish company Novo Nordisk announced a plan to invest approximately four billion yuan in Tianjin, and in July this year announced a further investment of approximately 800 million yuan to expand the quality control laboratory.

Podívejme sewhy this pharmaceutical giant so favours the Chinese market.

CMG